Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | DVL1 | O14640 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.51 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.51 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4905629 | 0.89 | ALDH1A1 (0.65) | HCAR2KDM4EALDH1A1HSD17B10SMN1; SMN2 | |
| SCHEMBL4915512 | 0.87 | KMT2A (0.68) | HCAR2KDM4EALDH1A1HSD17B10SMN1; SMN2 | |
| SCHEMBL4905601 | 0.86 | HCAR2 (0.58) | HCAR2KDM4EALDH1A1HSD17B10SMN1; SMN2 | |
| SCHEMBL4912940 | 0.84 | HCAR2 (0.58) | HCAR2KDM4EALDH1A1HSD17B10SMN1; SMN2 | |
| SCHEMBL3561950 | 0.83 | POLB (0.53) | HCAR2KDM4EALDH1A1HSD17B10SMN1; SMN2 | |
| SCHEMBL4914768 | 0.82 | KDM4E (0.59) | HCAR2KDM4EALDH1A1HSD17B10POLB | |
| SCHEMBL4917392 | 0.81 | ALDH1A1 (0.64) | HCAR2KDM4EALDH1A1HSD17B10SMN1; SMN2 | |
| SCHEMBL4914734 | 0.81 | SERPINE1 (0.62) | HCAR2KDM4EALDH1A1HSD17B10SMN1; SMN2 | |
| SCHEMBL4912970 | 0.81 | KDM4E (0.59) | HCAR2KDM4EALDH1A1HSD17B10POLB | |
| SCHEMBL4912722 | 0.78 | KDM4E (0.65) | HCAR2KDM4EALDH1A1HSD17B10POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269333-A1 | ANTHRANILIC ACID DERIVATIVES USEFUL IN TREATING INFECTION WITH HEPATITIS C VIRUS | WYETH (US) | 2008-10-30 | — | — | US | claimed |
| US-7408078-B2 | Anthranilic acid derivatives useful in treating infection with hepatitis C virus | WYETH (US) | 2008-08-05 | — | — | US | claimed |
| US-20050004192-A1 | Anthranilic acid derivatives useful in treating infection with hepatitis C virus | VIROPHARMA INCORPORATED | 2005-01-06 | — | — | US | claimed |
| WO-2004091724-A1 | ANTHRANILIC ACID DERIVATIVES USEFUL IN TREATING INFECTION WITH HEPATITIS C VIRUS | WYETH (US) | 2004-10-28 | — | — | WO | claimed |
| US-20080269333-A1 | ANTHRANILIC ACID DERIVATIVES USEFUL IN TREATING INFECTION WITH HEPATITIS C VIRUS | WYETH (US) | 2008-10-30 | — | — | US | disclosed |
| US-7408078-B2 | Anthranilic acid derivatives useful in treating infection with hepatitis C virus | WYETH (US) | 2008-08-05 | — | — | US | disclosed |
| US-20050004192-A1 | Anthranilic acid derivatives useful in treating infection with hepatitis C virus | VIROPHARMA INCORPORATED | 2005-01-06 | — | — | US | disclosed |
| WO-2004091724-A1 | ANTHRANILIC ACID DERIVATIVES USEFUL IN TREATING INFECTION WITH HEPATITIS C VIRUS | WYETH (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004192-A1 | Anthranilic acid derivatives useful in treating infection with hepatitis C virus | HCCS, ALAD, HAVCR2 | HCAR2 103/4885KDM4E 2214/4885ALDH1A1 271/4885 |
| US-20080269333-A1 | ANTHRANILIC ACID DERIVATIVES USEFUL IN TREATING INFECTION WITH HEPATITIS C VIRUS | HCCS, ALAD, HAVCR2 | HCAR2 103/4885KDM4E 2214/4885ALDH1A1 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.